MedTrace Logo

Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

NCT02899104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-03-31

No results posted yet for this study

Summary

Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG

Xofigo (Radium-223 dichloride, BAY88-8223)

Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-15
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02899104 on ClinicalTrials.gov